Method for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis with (-)-Nilvadipine Enantiomer
First Claim
1. A method for reducing Aβ
- deposition, Aβ
neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease or condition, comprising administering to the animal or human a therapeutically effective amount of enantiomerically-enriched (−
)-nilvadipine.
4 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods for reducing Aβ deposition, Aβ neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer'"'"'s disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (−)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of Aβ deposition, Aβ neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (−)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter.
-
Citations
14 Claims
-
1. A method for reducing Aβ
- deposition, Aβ
neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease or condition, comprising administering to the animal or human a therapeutically effective amount of enantiomerically-enriched (−
)-nilvadipine. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- deposition, Aβ
-
2. A method for reducing the risk of cerebral amyloidogenic disease or condition resulting from Aβ
- deposition, Aβ
neurotoxicity and microgliosis in an animal or human suffering from traumatic brain injury comprising administering to the animal or human a therapeutically effective amount of enantiomerically-enriched (−
)-nilvadipine, wherein the enantiomerically-enriched (−
)-nilvadipine administration begins following the acute head injury.
- deposition, Aβ
-
3. A method for reducing the risk of developing cerebral amyloidogenic disease or condition in an animal or human diagnosed with a risk for developing cerebral amyloidogenic disease or condition, comprising administering to the animal or human a therapeutically effective amount of enantiomerically-enriched (−
- )-nilvadipine.
-
14. A method for treating cerebral amyloidogenic disease or condition in an animal or human afflicted with a cerebral amyloidogenic disease or condition, comprising administering to the animal or human a composition consisting essentially of a therapeutically effective amount of enantiomerically-enriched (−
- )-nilvadipine, and a pharmaceutically acceptable carrier.
Specification